logo

For the Inventor, By the Inventor

Harlow, United Kingdom

Jag Paul Heer

This inventor holds 10 USPTO granted patents and 2 published patent applications and 7 EPO patents. Top assignees: Convergence Pharmaceuticals Limited, Glaxo Group Limited, Smithkline Beecham Corporation. Active years: 2002-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jag Paul Heer. Retrieved from https://idiyas.com/inventor/jag-paul-heer-yz50ptup

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Harlow, GB (2002 - 2013)
  • Cambridge, GB (2014)

Company Filing History:

goldMedal5 out of 24 
 
Convergence Pharmaceuticals Limited
 patents
silverMedal4 out of 1,170 
 
Glaxo Group Limited
 patents
bronzeMedal1 out of 2,198 
 
Smithkline Beecham Corporation
 patents

Years Active: 2002-2014

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 8697703 - [object Object] (2014-04-15),
2. 8536183 - 3-pyridylcarbonyl-piperazinylsulfonyl derivatives (2013-09-17),
3. 8530478 - Piperazine derivatives used as CAV2.2 calcium channel modulators (2013-09-10),
4. 8329730 - Compounds (2012-12-11),
5. 8288388 - 3-pyridylcarbonyl-piperazinylsulfonyl derivatives (2012-10-16),
6. 8278324 - Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) (2012-10-02),
7. 8263620 - Oxadiazole derivatives active on sphingosine-1-phosphate (SIP) (2012-09-11),
8. 8222245 - Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) (2012-07-17),
9. 8093249 - Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives (2012-01-10),
10. 6492378 - Substituted isoquinoline derivatives and their use as anticonvulsivants (2002-12-10),

Title: The Inventive Journey of Jag Paul Heer

Introduction:

Jag Paul Heer, a prolific inventor based in Harlow, GB, has made significant contributions to the field of pharmaceuticals with his innovative patent projects. With a total of 10 patents to his credit, Heer's work has focused on novel compounds and pharmaceutical compositions aimed at treating various diseases.

Latest Patents:

1. The present invention involves novel piperazine compounds designed to block calcium channels, particularly targeting Ca2.2 and Ca3.2 channels for therapeutic benefits in treating diseases such as pain.

2. Heer's patent on 3-pyridylcarbonyl-piperazinylsulfonyl derivatives showcases his dedication to developing effective treatments by focusing on blocking the Ca2.2 calcium channels.

Career Highlights:

Heer's career includes notable stints at Convergence Pharmaceuticals Limited and Glaxo Group Limited, where he honed his skills and expertise in the pharmaceutical industry. His innovative approach to drug development has led to the successful filing of numerous patents.

Collaborations:

During his professional journey, Heer has collaborated with industry experts such as Andrew Peter Cridland and Thomas Daniel Heightman. These partnerships have played a crucial role in fostering creativity and driving forward-thinking solutions in the pharmaceutical sector.

Conclusion:

Jag Paul Heer's inventive spirit and dedication to advancing pharmaceutical therapies have positioned him as a respected figure in the field of drug development. His patented compounds and pharmaceutical compositions stand as testament to his commitment to improving healthcare outcomes and enhancing patient quality of life.

Please let me know if you require further information or assistance.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…